<?xml version="1.0" encoding="UTF-8"?>
<p>Key differences in the new version of the model which depart from the original model include (a) no regression of antiviral cells back to susceptible status and (b) estimation of the rate of constitutive cellular acquisition of antiviral status (represented as Îµ), rather than fixation as a 0-1 scalar as in the first version of submission. We elaborate on the effects of these major changes to the model in answer to questions #2, 9, and 10 below.</p>
